View Item 

Show simple item record

Biomarker validation and testing
dc.contributor.authorHayes, Daniel F.
dc.date.accessioned2017-01-10T20:52:11Z
dc.date.available2017-01-10T20:52:11Z
dc.date.issued2015-05
dc.identifier.citation(2015). "Biomarker validation and testing." Molecular Oncology 9(5): 960-966.
dc.identifier.issn1574-7891
dc.identifier.issn1878-0261
dc.identifier.urihttps://hdl.handle.net/2027.42/135701
dc.publisherWiley Periodicals, Inc.
dc.publisherSpringer
dc.subject.otherTumor biomarkers
dc.subject.otherValidation
dc.subject.otherLevel of evidence
dc.titleBiomarker validation and testing
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumUniversity of Michigan Comprehensive Cancer Center, 6312 CCC, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5942, USA
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135701/1/mol2201595960.pdf
dc.identifier.doi10.1016/j.molonc.2014.10.004
dc.identifier.sourceMolecular Oncology
dc.identifier.citedreferenceAndre, F., McShane, L.M., Michiels, S., Ransohoff, D.F., Altman, D.G., Reis-Filho, J.S., Hayes, D.F., Pusztai, L., 2011. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 8, 171 – 176.
dc.identifier.citedreferenceFreidlin, B., McShane, L.M., Korn, E.L., 2010. Randomized clinical trials with biomarkers: design issues. J. Natl. Cancer Inst. 102, 152 – 160.
dc.identifier.citedreferenceHammond, M.E., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons, P.L., Francis, G., Goldstein, N.S., Hayes, M., Hicks, D.G., Lester, S., Love, R., Mangu, P.B., McShane, L., Miller, K., Osborne, C.K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J.N., Sweep, F.C., Taube, S., Torlakovic, E.E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R.B., Wittliff, J.L., Wolff, A.C., 2010. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784 – 2795.
dc.identifier.citedreferenceHammond, M.E., Hayes, D.F., Dowsett, M., Allred, D.C., Hagerty, K.L., Badve, S., Fitzgibbons, P.L., Francis, G., Goldstein, N.S., Hayes, M., Hicks, D.G., Lester, S., Love, R., Mangu, P.B., McShane, L., Miller, K., Osborne, C.K., Paik, S., Perlmutter, J., Rhodes, A., Sasano, H., Schwartz, J.N., Sweep, F.C., Taube, S., Torlakovic, E.E., Valenstein, P., Viale, G., Visscher, D., Wheeler, T., Williams, R.B., Wittliff, J.L., Wolff, A.C., 2010. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, e48 – e72.
dc.identifier.citedreferenceHayes, D.F., Allen, J., Compton, C., Gustavsen, G., Leonard, D.G., McCormack, R., Newcomer, L., Pothier, K., Ransohoff, D., Schilsky, R.L., Sigal, E., Taube, S.E., Tunis, S.R., 2013. Breaking a vicious cycle. Sci. Transl. Med. 5, 196cm196
dc.identifier.citedreferenceHayes, D.F., Bast, R.C., Desch, C.E., Fritsche, H., Kemeny, N.E., Jessup, J.M., Locker, G.Y., Macdonald, J.S., Mennel, R.G., Norton, L., Ravdin, P., Taube, S., Winn, R.J., 1996. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 88, 1456 – 1466.
dc.identifier.citedreferenceHenry, N.L., Hayes, D.F., 2006. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 11, 541 – 552.
dc.identifier.citedreferenceInstitute of Medicine, 2012. Evolution of Translational Omics: Lessons Learned and the Path Forward. The National Academies Press Washington, D.C
dc.identifier.citedreferenceMcShane, L.M., Hayes, D.F., 2012. Publication of tumor marker research results: the necessity for complete and transparent reporting. J. Clin. Oncol. 30, 4223 – 4232.
dc.identifier.citedreferenceMoher, D., Schulz, K.F., Altman, D.G., 2001. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann. Intern. Med. 134, 657 – 662.
dc.identifier.citedreferenceMoore, H.M., Kelly, A., McShane, L.M., Vaught, J., 2012. Biospecimen reporting for improved study quality (BRISQ). Clin. Chim. Acta. 413, 1305
dc.identifier.citedreferenceSargent, D.J., Conley, B.A., Allegra, C., Collette, L., 2005. Clinical trial designs for predictive marker validation in cancer treatment trials. J. Clin. Oncol. 23, 2020 – 2027.
dc.identifier.citedreferenceSchilsky, R.L., 2009. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J. Clin. Oncol. 27, 3725 – 3730.
dc.identifier.citedreferenceSimon, R.M., Paik, S., Hayes, D.F., 2009. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl. Cancer Inst. 101, 1446 – 1452.
dc.identifier.citedreferenceTeutsch, S.M., Bradley, L.A., Palomaki, G.E., Haddow, J.E., Piper, M., Calonge, N., Dotson, W.D., Douglas, M.P., Berg, A.O., 2009. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: methods of the EGAPP working group. Genet. Med. 11, 3 – 14.
dc.identifier.citedreferenceWolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., Allred, D.C., Bartlett, J.M., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Mangu, P.B., Paik, S., Perez, E.A., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., Hayes, D.F., 2013. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline update. Arch. Pathol. Lab. Med.
dc.identifier.citedreferenceWolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., Allred, D.C., Bartlett, J.M., Bilous, M., Fitzgibbons, P., Hanna, W., Jenkins, R.B., Mangu, P.B., Paik, S., Perez, E.A., Press, M.F., Spears, P.A., Vance, G.H., Viale, G., Hayes, D.F., 2013. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997 – 4013.
dc.identifier.citedreferenceAJCC, 2010. Breast. In Edge, S.B., Byrd, D.R., Compton, C., Fritz, A.G., Greene, F.L., Trotti, A. (Eds.), AJCC Staging Manual. Seventh ed. Springer New York, Dordrecht, Heidelberg, London
dc.identifier.citedreferenceAltman, D.G., McShane, L.M., Sauerbrei, W., Taube, S.E., 2012. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. Plos Med. 9, e1001216
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mol2201595960.pdf
Size:
1.071MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.